Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Qualitative evaluation of the use of modelling in resource allocation decisions for HIV and TB

Anna L Bowring, Debra ten Brink, Rowan Martin-Hughes, Nicole Fraser-Hurt, Nejma Cheikh, Nick Scott
doi: https://doi.org/10.1101/2023.04.11.23288405
Anna L Bowring
1Burnet Institute, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: anna.bowring{at}burnet.edu.au
Debra ten Brink
1Burnet Institute, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rowan Martin-Hughes
1Burnet Institute, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Fraser-Hurt
2The World Bank, Washington DC, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nejma Cheikh
2The World Bank, Washington DC, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick Scott
1Burnet Institute, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Globally, resources for health spending, including HIV and tuberculosis (TB), are constrained, and a substantial gap exists between spending and estimated needs. Optima is an allocative efficiency modeling tool that has been used since 2010 in over 50 settings to generate evidence for country-level HIV and TB resource allocation decisions. This evaluation assessed the utilization of modeling to inform financing priorities from the perspective of country stakeholders and their international partners.

Methods In October-December 2021, the World Bank and Burnet Institute led 16 semi-structured small-group virtual interviews with 54 representatives from national governments and international health and funding organizations. Interviews probed participants’ roles and satisfaction with Optima analyses and how model findings have had been used and impacted resource allocation. Interviewed stakeholders represented nine countries and 11 different disease program-country contexts with prior Optima modeling analyses. Interview notes were thematically analyzed to assess factors influencing the utilization of modeling evidence in health policy and outcomes.

Results Common influences on utilization of Optima findings encompassed the perceived validity of findings, health system financing mechanisms, the extent of stakeholder participation in the modeling process, engagement of funding organization, socio-political context, and timeliness of the analysis. Utilizing workshops can facilitate effective stakeholder engagement and collaboration.

Model findings were often used conceptually to localize global evidence and facilitate discussion. Secondary outputs included informing strategic and financial planning, funding advocacy, grant proposals, and influencing investment shifts.

Conclusion Allocative efficiency modeling has supported evidence-informed decision making in numerous contexts and enhanced the conceptual and practical understanding of allocative efficiency. Most immediately, greater involvement of country stakeholders in modeling studies and timing studies to key strategic and financial planning decisions may increase the impact on decision making. Better consideration for integrated disease modeling, equity goals, and financing constraints may improve relevance and utilization of modeling findings.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was funded by the World Bank, who contributed to study design, implementation, analysis, interpretation and manuscript review. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The original QA exercise was not subject to ethics review. The Alfred Hospital Ethics Review Committee approved the collation and analysis of the program QA data (project number:158/22).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • Revised Methods to add further details on Optima models and qualitative analysis; Revised introduction and discussion to positions the analysis within existing literature and conceptual frameworks; Results section updated with additional quotes.

Data Availability

Data from this evaluation is not available for sharing as per ethics agreements. Data and reports for underlying country models are published and openly available in the World Bank Open Knowledge Repository and through Optima.

https://openknowledge.worldbank.org/

http://optimamodel.com/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 26, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Qualitative evaluation of the use of modelling in resource allocation decisions for HIV and TB
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Qualitative evaluation of the use of modelling in resource allocation decisions for HIV and TB
Anna L Bowring, Debra ten Brink, Rowan Martin-Hughes, Nicole Fraser-Hurt, Nejma Cheikh, Nick Scott
medRxiv 2023.04.11.23288405; doi: https://doi.org/10.1101/2023.04.11.23288405
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Qualitative evaluation of the use of modelling in resource allocation decisions for HIV and TB
Anna L Bowring, Debra ten Brink, Rowan Martin-Hughes, Nicole Fraser-Hurt, Nejma Cheikh, Nick Scott
medRxiv 2023.04.11.23288405; doi: https://doi.org/10.1101/2023.04.11.23288405

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Policy
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)